SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator 1-eye-jack, joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 5/29/2015 12:57:40 PM - Followers: 735 - Board type: Free - Posts Today: 33



Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 
 
    

 



 
PRESS RELEASES & NEWS ARTICLES

Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015 - Presentation and Webcast on May 28, 2015, at 9:00 a.m Eastern Time.
May 26, 2015
Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing  -  Following the reverse split, there will be approximately 7 million common shares outstanding.

May 22, 2015
Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -  Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview  - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -     
May 20, 2015   
Amarantus to Present at Two Upcoming Investor Conferences
May 19, 2015 

Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015

Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease  -  Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
May 13, 2015
Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
May 11, 2015

Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015 
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015

Developing clinical-stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015
April 9, 2015
Amarantus Reports 2014 Financial Results and Business Overview - 
 First pharmaceutical customer in the first quarter of 2015, garnered its first pharmaceutical customer in the first quarter of 2015, as the interest in trials of experimental Alzheimer's therapies is beginning to increase with high-profile successes renewing hope for the field.
April 7, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
More News

 


Predicting Alzheimer's before it starts
Published on Apr. 8, 2015
 

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
 

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014
 

Amarantus BioScience
Oct. 19, 2014

 

 

 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

info@vstocktransfer.com

www.VStockTransfer.com 


 
 
 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
 

                                                                            4 Conferences
 LD Micro Invitational Presentation & Webcast - June 2, 2015, 1:30 p.m. EDT / 10:30 a.m. PDT, Luxe Sunset Boulevard, Los Angeles, CA
•  Bio International Convention - Philadelphia, PA - June 15-18, 2015, 
•  Alzheimer's Association International Conference  AAIC>.15   -  July 18-23, 2015, Washington, D.C. United States
•  
UN Brain Health Summoit - United Nations, NYC - July 22, 2015         

       
A webcast of the SeeThru Equity 4th Annual Microcap Investor Conference and LD Micro presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.            

            
        smiley    BUSINESS UPDATE CONFERENCE CALL - Presentation (PDF)  May 27, 2015   yes
       Amarantus BioScience's (AMBS) CEO Gerald Commissiong Hosts Business Update Conference Call (Transcript)

                 SeeThru Equity 4th Annual Microcap Investor Conference - Webcast 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 05/28/2015 06:16:34 AM
AMBS News: Current Report Filing (8-k) 05/26/2015 10:09:39 AM
AMBS News: Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015 05/26/2015 07:05:00 AM
AMBS News: Notice of Effectiveness (effect) 05/26/2015 06:01:32 AM
AMBS News: Notice of Effectiveness (effect) 05/26/2015 06:01:32 AM
PostSubject
#113003  Sticky Note From the new Zack's Research Report(Apr '15) "AMBS cjstocksup 04/29/15 04:15:17 PM
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#114815   I am completely fine with that for now, Gharet 05/29/15 12:57:40 PM
#114814   Everyone believes him. That's why the PPS didn't brharris 05/29/15 11:29:44 AM
#114812   I guess Napadano's new article on AMBS is Alapis 05/29/15 10:37:53 AM
#114811   i believe the bumps from now on are Alapis 05/29/15 10:34:32 AM
#114810   I'm very confident that said prediction will end SidVicious 05/29/15 10:33:16 AM
#114809   I think the Risk vs Reward in AMBS Yankeedave 05/29/15 10:30:43 AM
#114808   Honestly, because nothing fundamentally has changed. The company SidVicious 05/29/15 10:28:07 AM
#114805   i'm very confident that we will trade at Alapis 05/29/15 10:12:01 AM
#114804   no one believes him der_deutschetrader 05/29/15 10:10:30 AM
#114803   NASDAQ IPO: Why Now? • Core fundamentals have Yankeedave 05/29/15 10:09:16 AM
#114802   let's see der_deutschetrader 05/29/15 10:08:54 AM
#114801   this is nothing new and has nothing to Alapis 05/29/15 10:03:44 AM
#114800   One thing is for sure. Nothing Gerald says SidVicious 05/29/15 09:49:11 AM
#114799   Gerald also thought he had the catalysts to SidVicious 05/29/15 09:31:20 AM
#114798   TOXIC Financier DOMINION adds nearly 5% to ownership. Sgt. Pepper 05/29/15 09:29:46 AM
#114797   This SCAM will be $6 NOBODY buying at Sgt. Pepper 05/29/15 09:29:31 AM
#114796   SCAM AMBS has $109 Direct quote from their Sgt. Pepper 05/29/15 09:29:18 AM
#114795   TOXIC FINANCIER Dominion is the LARGEST shareholder Sgt. Pepper 05/29/15 09:29:04 AM
#114794   Beware! 150:1 Split in this SCAM Coming.BEWARE! Sgt. Pepper 05/29/15 09:28:52 AM
#114793   Yes it does. Noteholders can convert easily at GS1 05/29/15 09:22:11 AM
#114792   if they have an NDA they just CAN'T...and Alapis 05/29/15 09:11:48 AM
#114791   I believe the float would be aprox. 7-MM JPetroInc 05/29/15 09:00:07 AM
#114790   I get the feeling by how GC talked brharris 05/29/15 07:37:12 AM
#114789   2 billion / 150 = 13,333,333 brharris 05/29/15 07:28:22 AM
#114788   The thing that is confusing to me is GS1 05/29/15 06:43:07 AM
#114786   especially in light of the published middling numbers joboggi 05/29/15 06:21:08 AM
#114785   Neurotrope Bioscience (OTC:NTRP) has AD Diagnostic test done GS1 05/29/15 05:59:23 AM
#114784   Would you know the number of A S klouis 05/29/15 03:58:30 AM
#114783   That's your personal opinion, I presume. Otherwise I sante1 05/29/15 01:55:40 AM
#114782   Confidential agreement signed. Lympro will be sold, but mazennnn 05/28/15 10:59:10 PM
#114781   Wow. Thanks for that. I will michelebucks 05/28/15 10:47:12 PM
#114780   From the conf call: Now as far as the brharris 05/28/15 08:48:37 PM
#114771   No worries man I'm done posting, going to Gharet 05/28/15 07:06:48 PM
#114770   I'm comfortable with my 15+ million shares and Gharet 05/28/15 07:05:48 PM
#114768   late breaking? The data was collected last year, joboggi 05/28/15 06:57:45 PM
#114766   Here is the statement from the conference call brharris 05/28/15 06:05:20 PM
#114765   For those interested: http://seekingalpha.com/article/3216786-amarantus-bioscie brharris 05/28/15 06:00:28 PM
#114764   Also GC stated in the conference call that brharris 05/28/15 05:48:55 PM
#114763   Hold your horses till the abstracts are posted. powerc 05/28/15 05:05:07 PM
#114761   well well well...it looks like the pps is Alapis 05/28/15 04:09:04 PM
#114759   Beware! 150:1 Split in this SCAM Coming.BEWARE! Sgt. Pepper 05/28/15 03:47:12 PM
#114758   Nice new graphics and all looks good but Ragnaroc 05/28/15 03:40:08 PM
#114756   All your questions were answered in yesterday's conference brharris 05/28/15 12:34:12 PM
#114755   http://www.alz.org/research/search.asp?cof=FORID%3A11&ie=UTF-8&q=lympro&sa.x=0&s joboggi 05/28/15 12:21:49 PM
#114754   you don't go all the way to Denmark joboggi 05/28/15 12:19:33 PM
#114753   If you sell stock at five cents, as joboggi 05/28/15 12:07:47 PM
#114752   Who is buying today? JJAAMMAANN 05/28/15 11:52:08 AM
#114751   so many things going on here..as per the Alapis 05/28/15 11:48:05 AM
#114749   The Georgetown test has been administered to more joboggi 05/28/15 11:40:10 AM
#114748   the window for cheap shares is closing..... Alapis 05/28/15 11:14:54 AM
PostSubject